Combination Intraperitoneal Chemotherapy Is Superior to Mitomycin C or Oxaliplatin for Colorectal Carcinomatosis In Vivo

Background Hyperthermic intraperitoneal (IP) chemotherapy after cytoreduction improves survival in patients with colorectal carcinomatosis of the peritoneal surface. Most protocols use single agents (mitomycin C or oxaliplatin) provided IP. The purpose of this study was to determine whether combination IP chemotherapy is superior to single-agent therapy in a mouse model.